The role of molecular pathology in non-small-cell lung carcinoma—now and in the future

Por Brandao, G.D.A., Brega, E.F., Spatz, A.
Publicado em 2012

An experimental inter-expert telepathology network using static imaging

Por Tucker, J, Busch, C, Spatz, A, Wells, C, Brugal, G
Publicado em 2001

In vivo evolution of tumour cells after the generation of double-strand DNA breaks

Por Mekid, H, Tounekti, O, Spatz, A, Cemazar, M, El Kebir, F Z, Mir, L M
Publicado em 2003

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?

Por Paliga, A, Onerheim, R, Gologan, A, Chong, G, Spatz, A, Niazi, T, Garant, A, Macheto, D, Alcindor, T, Vuong, T
Publicado em 2012

Biomarkers in melanoma

Por Gogas, H., Eggermont, A. M. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R.
Publicado em 2009

EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer

Por Kamel–Reid, S., Chong, G., Ionescu, D.N., Magliocco, A.M., Spatz, A., Tsao, M., Weng, X., Young, S., Zhang, T., Soulieres, D.
Publicado em 2012

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients

Por El Hajj, P, Journe, F, Wiedig, M, Laios, I, Salès, F, Galibert, M-D, Van Kempen, L C, Spatz, A, Badran, B, Larsimont, D, Awada, A, Ghanem, G
Publicado em 2013

Comprehensive analysis of CDKN2A (p16(INK4A)/p14(ARF)) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma

Por Laud, K, Marian, C, Avril, M F, Barrois, M, Chompret, A, Goldstein, A M, Tucker, M A, Clark, P A, Peters, G, Chaudru, V, Demenais, F, Spatz, A, Smith, M W, Lenoir, G M, Paillerets, B Bressac‐de
Publicado em 2006